Delaware
|
11-3054851
|
|
(State or Other Jurisdiction
|
(I.R.S. Employer
|
|
of Incorporation or Organization)
|
Identification No.)
|
Large accelerated filer ☐
|
Accelerated filer
|
☒ |
Non-accelerated filer ☐
|
Smaller reporting company
|
☐ |
Emerging growth company | ☐ |
Class of Stock
|
Outstanding November 8, 2018
|
Common Stock ($.001 par value)
|
7,278,139 |
Page
|
||
PART I – FINANCIAL INFORMATION
|
||
ITEM 1.
|
Financial Statements
|
|
4 |
||
4
|
||
5
|
||
6
|
||
7
|
||
ITEM 2.
|
20
|
|
ITEM 3.
|
28
|
|
ITEM 4.
|
29
|
PART II – OTHER INFORMATION
|
||
ITEM 1.
|
29
|
|
ITEM 1A.
|
29
|
|
ITEM 2.
|
30
|
|
ITEM 6.
|
31
|
|
32
|
September 30,
2018(1)
|
December 31,
2017 |
|||||||
(unaudited)
|
(audited)
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
13,381,013
|
$
|
7,333,810
|
||||
Short term investments
|
58,429,211
|
51,973,971
|
||||||
Accounts receivable
|
14,455,354
|
4,655,105
|
||||||
Deferred royalty buy-down
|
601,660
|
1,794,126
|
||||||
Prepaid expenses and other current assets
|
801,956
|
623,503
|
||||||
Total current assets
|
87,669,194
|
66,380,515
|
||||||
Long-term investments
|
5,168,322
|
5,745,974
|
||||||
Deferred royalty buy-down – long term, net
|
-
|
732,206
|
||||||
Deferred tax assets, net
|
275,526
|
1,739,706
|
||||||
Patent costs, net
|
439,892
|
397,993
|
||||||
Total assets
|
$
|
93,552,934
|
$
|
74,996,394
|
||||
Liabilities and stockholders’ equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued expenses
|
$
|
1,116,463
|
$
|
933,998
|
||||
Income tax payable
|
694,050
|
68,733
|
||||||
Deferred revenue
|
-
|
1,057,979
|
||||||
Accrued liabilities of discontinued operations
|
-
|
78,138
|
||||||
Total current liabilities
|
1,810,513
|
2,138,848
|
||||||
Long-term deferred revenue
|
-
|
5,340,708
|
||||||
Stockholders’ equity:
|
||||||||
Series A Preferred stock, $.50 par value, 700,000 shares authorized; none outstanding
|
-
|
-
|
||||||
Common stock, $.001 par value; 10,000,000 shares authorized; 7,738,167 and 7,600,167 shares issued, 7,283,528
and 7,189,233 shares outstanding as of September 30, 2018 and December 31, 2017, respectively
|
7,738
|
7,600
|
||||||
Additional paid-in capital
|
36,198,898
|
33,468,323
|
||||||
Retained earnings
|
65,993,035
|
41,939,115
|
||||||
Treasury stock, 454,639 and 410,934 shares at cost as of September 30, 2018 and December 31, 2017,
respectively
|
(10,457,250
|
)
|
(7,898,200
|
)
|
||||
Total stockholders’ equity
|
91,742,421
|
67,516,838
|
||||||
Total liabilities and stockholders’ equity
|
$
|
93,552,934
|
$
|
74,996,394
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2018(1)
|
2017
|
2018(1)
|
2017
|
|||||||||||||
Revenues:
|
||||||||||||||||
Royalties
|
$
|
8,168,081
|
$
|
6,511,700
|
$
|
23,068,585
|
$
|
20,729,017
|
||||||||
Licensing revenues
|
-
|
4,408
|
39,679
|
13,226
|
||||||||||||
Total Revenues
|
8,168,081
|
6,516,108
|
23,108,264
|
20,742,243
|
||||||||||||
Costs and expenses:
|
||||||||||||||||
Research and development
|
162,625
|
356,847
|
569,648
|
949,359
|
||||||||||||
General and administrative
|
2,232,077
|
2,175,501
|
6,345,662
|
6,916,501
|
||||||||||||
Total Cost and Expenses
|
2,394,702
|
2,532,348
|
6,915,310
|
7,865,860
|
||||||||||||
Operating income
|
5,773,379
|
3,983,760
|
16,192,954
|
12,876,383
|
||||||||||||
Other income:
|
||||||||||||||||
Interest income
|
359,637
|
193,462
|
851,334
|
436,210
|
||||||||||||
Other income
|
-
|
14,667
|
96,663
|
40,651
|
||||||||||||
359,637
|
208,129
|
947,997
|
476,861
|
|||||||||||||
Income before income tax expense
|
6,133,016
|
4,191,889
|
17,140,951
|
13,353,244
|
||||||||||||
Provision for income tax expense
|
(1,089,966
|
)
|
(1,477,057
|
)
|
(3,271,366
|
)
|
(4,669,569
|
)
|
||||||||
Net income
|
$
|
5,043,050
|
$
|
2,714,832
|
$
|
13,869,585
|
$
|
8,683,675
|
||||||||
Basic net income per share
|
$
|
0.69
|
$
|
0.38
|
$
|
1.92
|
$
|
1.21
|
||||||||
Diluted net income per share
|
$
|
0.69
|
$
|
0.37
|
$
|
1.89
|
$
|
1.19
|
||||||||
Shares used in computation of basic net income per share
|
7,281,388
|
7,164,934
|
7,230,106
|
7,166,470
|
||||||||||||
Shares used in computation of diluted net income per share
|
7,356,885
|
7,314,609
|
7,327,029
|
7,325,602
|
Nine Months Ended
September 30,
|
||||||||
Cash flows from operating activities:
|
2018(1)
|
2017
|
||||||
Net income
|
$
|
13,869,585
|
$
|
8,683,675
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Amortization
|
1,984,577
|
1,632,823
|
||||||
Stock-based compensation expense
|
159,883
|
100,428
|
||||||
Deferred tax expense
|
128,418
|
298,121
|
||||||
Extinguishment of accrued liabilities
|
(78,138
|
)
|
-
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(2,245,522
|
)
|
(871,093
|
)
|
||||
Income tax receivable
|
(774,624
|
)
|
437,781
|
|||||
Prepaid expenses and other current assets
|
(178,453
|
)
|
(48,719
|
)
|
||||
Patent costs
|
(95,399
|
)
|
-
|
|||||
Accounts payable and accrued expenses
|
(356,548
|
)
|
46,626
|
|||||
Deferred revenue
|
(139,680
|
)
|
(907,776
|
)
|
||||
Net cash provided by operating activities
|
12,274,099
|
9,371,866
|
||||||
Cash flows from investing activities:
|
||||||||
Maturity of marketable investments
|
58,380,000
|
43,579,082
|
||||||
Purchases of marketable investments
|
(64,618,676
|
)
|
(50,933,705
|
)
|
||||
Net cash used in investing activities
|
(6,238,676
|
)
|
(7,354,623
|
)
|
||||
Cash flows from financing activities:
|
||||||||
Proceeds from stock option exercises
|
2,570,830
|
258,250
|
||||||
Payments for repurchase of common stock
|
(2,559,050
|
)
|
(616,499
|
)
|
||||
Net cash provided by (used in) financing activities
|
11,780
|
(358,249
|
)
|
|||||
Increase in cash and cash equivalents
|
6,047,203
|
1,658,994
|
||||||
Cash and cash equivalents at beginning of year
|
7,333,810
|
4,763,364
|
||||||
Cash and cash equivalents at end of period
|
$
|
13,381,013
|
$
|
6,422,358
|
||||
Supplemental disclosures of cash flow information:
|
||||||||
Cash paid during the period for:
|
||||||||
Interest
|
-
|
-
|
||||||
Taxes
|
$
|
3,917,572
|
$
|
4,410,000
|
1.
|
RESTATEMENT OF PREVIOUSLY REPORTED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
|
June 30, 2018
Condensed Consolidated Balance Sheet |
||||||||||||
As Reported
|
Adjustments
|
Restated
|
||||||||||
Assets
|
||||||||||||
Accounts Receivable
|
$
|
12,893,893
|
$
|
754,365
|
$
|
13,648,258
|
||||||
Total Current Assets
|
81,402,261
|
754,365
|
82,156,626
|
|||||||||
Total Assets
|
89,330,315
|
754,365
|
90,084,680
|
|||||||||
Liabilities
|
||||||||||||
AP and Accrued Liabilities
|
1,591,707
|
58,740
|
1,650,447
|
|||||||||
Income Tax Payable
|
801,800
|
148,361
|
950,161
|
|||||||||
Total Current Liabilities
|
2,393,507
|
207,101
|
2,600,608
|
|||||||||
Stockholders' Equity
|
||||||||||||
Retained Earnings
|
60,402,721
|
547,264
|
60,949,985
|
|||||||||
Total Stockholders' Equity
|
86,936,808
|
547,264
|
87,484,072
|
|||||||||
Total Liabilities and Stockholders' Equity
|
$
|
89,330,315
|
$
|
754,365
|
$
|
90,084,680
|
Condensed Consolidated Income Statements
|
||||||||||||||||||||||||
Three months ended June 30, 2018
|
Six months ended June 30, 2018
|
|||||||||||||||||||||||
As
Reported
|
Adjustments
|
Restated
|
As
Reported
|
Adjustments
|
Restated
|
|||||||||||||||||||
Revenues
|
||||||||||||||||||||||||
Royalties
|
$
|
7,061,139
|
$
|
754,365
|
$
|
7,815,504
|
$
|
14,146,139
|
$
|
754,365
|
$
|
14,900,504
|
||||||||||||
Total Revenues
|
7,096,409
|
754,365
|
7,850,774
|
14,185,818
|
754,365
|
14,940,183
|
||||||||||||||||||
Cost and expenses
|
||||||||||||||||||||||||
General and administrative
|
1,985,212
|
58,740
|
2,043,952
|
4,054,845
|
58,740
|
4,113,585
|
||||||||||||||||||
Total cost and expenses
|
2,197,008
|
58,740
|
2,255,748
|
4,461,868
|
58,740
|
4,520,608
|
||||||||||||||||||
Operating income
|
4,899,401
|
695,625
|
5,595,026
|
9,723,950
|
695,625
|
10,419,575
|
||||||||||||||||||
Income before income tax expense
|
5,255,132
|
695,625
|
5,950,757
|
10,312,310
|
695,625
|
11,007,935
|
||||||||||||||||||
Provision for income tax expense
|
(954,465
|
)
|
(148,361
|
)
|
(1,102,826
|
)
|
(2,033,039
|
)
|
(148,361
|
)
|
(2,181,400
|
)
|
||||||||||||
Net income
|
$
|
4,300,667
|
$
|
547,264
|
$
|
4,847,931
|
$
|
8,279,271
|
$
|
547,264
|
$
|
8,826,535
|
||||||||||||
Basic net income per share
|
$
|
0.60
|
$
|
0.67
|
$
|
1.15
|
$
|
1.23
|
||||||||||||||||
Diluted net income per share
|
$
|
0.59
|
$
|
0.66
|
$
|
1.13
|
$
|
1.21
|
Condensed Consolidated Statement of Cash Flow
Six months ended June 30, 2018
|
||||||||||||
As Reported
|
Adjustments
|
Restated
|
||||||||||
Cash Flows from Operating Activities
|
||||||||||||
Net Income
|
$
|
8,279,271
|
$
|
547,264
|
$
|
8,826,535
|
||||||
Changes in Operating Assets and Liabilities:
|
||||||||||||
Accounts Receivable
|
(684,061
|
)
|
(754,365
|
)
|
(1,438,426
|
)
|
||||||
Income tax receivable
|
(666,874
|
)
|
148,361
|
(518,513
|
)
|
|||||||
Accounts payable and accrued expenses
|
118,696
|
58,740
|
177,436
|
2.
|
ORGANIZATION AND DESCRIPTION OF BUSINESS
|
3.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
As reported
December 31, 2017
|
Adjustments
|
Adjusted
January 1, 2018
|
||||||||||
Accounts receivable
|
$
|
4.7
|
$
|
7.6
|
(1)
|
$
|
12.3
|
|||||
Deferred revenue
|
(6.4
|
)
|
6.3
|
(2)
|
(0.1
|
)
|
||||||
Deferred royalty buy-down
|
(2.5
|
)
|
(0.4
|
)(3)
|
(2.9
|
)
|
||||||
Accounts payable and accrued expenses
-third party royalties
|
(0.4
|
)
|
(0.5
|
)(3)
|
(0.9
|
)
|
||||||
Deferred tax assets, net
|
1.7
|
(1.3
|
)(4)
|
0.4
|
||||||||
Income tax payable
|
-
|
(1.4
|
)(5)
|
(1.4
|
)
|
|||||||
Retained earnings adjustment
|
$
|
(2.9
|
)
|
$
|
10.3
|
$
|
7.4
|
(1)
|
This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold
revenues reported to us by Endo for the fourth quarter of 2017.
|
(2) |
Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.
|
(3) |
Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for
the fourth quarter of 2017.
|
(4) |
To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.
|
(5) |
To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods
sold revenues reported to us by Endo for the fourth quarter of 2017.
|
September 30, 2018
|
||||||||||||
As Reported
|
Balances Without
Adoption of New
Revenue Standard
|
Effect of Change
Higher / (Lower)
|
||||||||||
Assets
|
||||||||||||
Accounts receivable
|
$
|
14.5
|
$
|
6.3
|
$
|
8.2
|
||||||
Deferred royalty buy-down
|
0.6
|
0.7 |
(0.1
|
)
|
||||||||
Deferred tax assets
|
0.3
|
1.5
|
(1.2
|
)
|
||||||||
Liabilities
|
||||||||||||
Accounts payable and accrued expenses
|
1.1
|
0.5
|
0.6
|
|||||||||
Deferred revenue
|
-
|
1.0
|
(1.0
|
)
|
||||||||
Income tax payable
|
0.7
|
(0.6
|
) |
1.3
|
|
|||||||
Deferred revenue, long term
|
-
|
4.5
|
(4.5
|
)
|
||||||||
Equity
|
||||||||||||
Retained earnings
|
66.0
|
55.5
|
10.5
|
Three Months Ended September 30, 2018
|
||||||||||||
As Reported
|
Balances Without
Adoption of New
Revenue Standard
|
Effect of Change
Higher / (Lower)
|
||||||||||
Revenues
|
||||||||||||
Royalties
|
$
|
8.2
|
$
|
8.1
|
$
|
0.1
|
||||||
Costs and expenses
|
||||||||||||
General and administrative
|
$
|
2.2
|
$
|
2.2
|
$
|
-
|
||||||
Provision for income taxes
|
1.1
|
1.1
|
-
|
|||||||||
Net income
|
5.0
|
4.9
|
0.1
|
Nine Months Ended September 30, 2018
|
||||||||||||
As Reported
|
Balances Without
Adoption of New
Revenue Standard
|
Effect of Change
Higher / (Lower)
|
||||||||||
Revenues
|
||||||||||||
Royalties
|
$
|
23.1
|
$
|
23.1
|
$
|
-
|
||||||
Costs and expenses
|
||||||||||||
General and administrative
|
$
|
6.3
|
$
|
6.3
|
$
|
-
|
||||||
Provision for income taxes
|
3.3
|
3.5
|
(0.2
|
) |
||||||||
Net income
|
13.9
|
13.7
|
0.2
|
Maturities as of
September 30, 2018
|
Maturities as of
December 31, 2017
|
|||||||||||||||
1 Year or
Less
|
Greater than 1
Year
|
1 Year or
Less
|
Greater than
1 Year
|
|||||||||||||
Municipal bonds
|
$
|
4,285,175
|
$
|
100,000
|
$
|
1,002,650
|
$
|
100,000
|
||||||||
Corporate bonds
|
49,052,966
|
4,819,306
|
48,143,495
|
3,155,573
|
||||||||||||
Certificates of deposit
|
5,091,070
|
249,016
|
2,827,826
|
2,490,401
|
||||||||||||
Total
|
$
|
58,429,211
|
$
|
5,168,322
|
$
|
51,973,971
|
$
|
5,745,974
|
September 30, 2018
|
Type of Instrument
|
Fair Value
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Cash equivalents
|
Institutional Money Market
|
$
|
9,491,019
|
$
|
9,491,019
|
$
|
-
|
$
|
-
|
||||||||
Cash equivalents
|
Corporate Bonds
|
1,300,000
|
1,300,000
|
-
|
-
|
||||||||||||
Investments
|
Municipal Bonds
|
4,385,175
|
-
|
4,385,175
|
-
|
||||||||||||
Investments
|
Corporate Bonds
|
53,872,272
|
-
|
53,872,272
|
-
|
||||||||||||
Investments
|
Certificates of Deposit
|
5,340,086
|
5,340,086
|
-
|
-
|
December 31, 2017
|
Type of Instrument
|
Fair Value
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Cash equivalents
|
Institutional Money Market
|
$
|
3,108,549
|
$
|
3,108,549
|
$
|
-
|
$
|
-
|
||||||||
Cash equivalents
|
Municipal Bonds
|
800,000
|
-
|
800,000
|
-
|
||||||||||||
Investments
|
Municipal Bonds
|
1,102,650
|
-
|
1,102,650
|
-
|
||||||||||||
Investments
|
Corporate Bonds
|
51,299,068
|
-
|
51,299,068
|
-
|
||||||||||||
Investments
|
Certificates of Deposit
|
5,318,227
|
5,318,227
|
-
|
-
|
Nine Months Ended
September 30, 2018
|
||||
Risk-free interest rate
|
2.62% to 2.81%
|
|||
Expected term of option
|
6.25 years
|
|||
Expected stock price volatility
|
39.6% to 39.7%
|
|||
Expected dividend yield
|
$
|
0.0
|
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Term
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Outstanding at December 31, 2017
|
232,000
|
$
|
21.56
|
2.52
|
$
|
5,050,990
|
||||||||||
Grants
|
31,500
|
41.79
|
-
|
-
|
||||||||||||
Exercised
|
(138,000
|
)
|
18.63
|
-
|
3,720,149
|
|||||||||||
Forfeitures or expirations
|
-
|
-
|
-
|
-
|
||||||||||||
Outstanding at September 30, 2018
|
125,500
|
$
|
29.86
|
5.16
|
$
|
3,593,430
|
||||||||||
Exercisable at September 30, 2018
|
86,500
|
$
|
24.84
|
3.47
|
$
|
2,910,945
|
4.
|
NET INCOME PER SHARE
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2018
|
2017
|
2018
|
2017
|
|||||||||||||
Stock options
|
-
|
20,000
|
-
|
20,000
|
5.
|
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
|
September 30,
2018
|
December 31,
2017
|
|||||||
Trade accounts payable
|
$
|
122,485
|
$
|
152,542
|
||||
Accrued legal and other professional fees
|
200,116
|
150,691
|
||||||
Accrued payroll and related costs
|
183,435
|
215,322
|
||||||
Third party royalties
|
589,274
|
329,211
|
||||||
Other accruals
|
21,153
|
86,232
|
||||||
Total
|
$
|
1,116,463
|
$
|
933,998
|
6.
|
PATENT COSTS
|
September 30,
2018
|
December 31,
2017
|
|||||||
Patents
|
1,020,416
|
$
|
925,016
|
|||||
Accumulated amortization
|
(580,524
|
)
|
(527,023
|
)
|
||||
$
|
439,892
|
$
|
397,993
|
October 1, 2018 - December 31, 2018
|
$
|
19,400
|
||
2019
|
72,700
|
|||
2020
|
55,800
|
|||
2021
|
38,900
|
|||
2022
|
38,900
|
|||
Thereafter
|
214,200
|
7.
|
PROVISION FOR INCOME TAXES
|
7.
|
SUBSEQUENT EVENTS
|
Three Months Ended
September 30, 2018
|
Three Months Ended
September 30, 2017
|
|||||||
Program
|
||||||||
Uterine Fibroids
|
$
|
82,716
|
$
|
129,276
|
||||
Pre-clinical/other research projects
|
79,909
|
227,571
|
· |
the nature, timing and estimated costs of the efforts necessary to complete the development of our drug candidate projects;
|
· |
the anticipated completion dates for our drug candidate projects;
|
· |
the scope, rate of progress and cost of our clinical trials that we are currently running or may commence in the future with respect to our drug candidate projects;
|
· |
the scope, rate of progress of our preclinical studies and other R&D activities related to our drug candidate projects;
|
· |
clinical trial results for our drug candidate projects;
|
· |
the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights relating to our drug candidate projects;
|
· |
the terms and timing of any strategic alliance, licensing and other arrangements that we have or may establish in the future relating to our drug candidate projects;
|
· |
the cost and timing of regulatory approvals with respect to our drug candidate projects; and
|
· |
the cost of establishing clinical supplies for our drug candidate projects.
|
Nine Months Ended
September 30, 2018
|
Nine Months Ended
September 30, 2017
|
|||||||
Program
|
||||||||
Uterine Fibroids
|
$
|
210,250
|
$
|
357,409
|
||||
Pre-clinical/other research projects
|
359,398
|
591,950
|
· |
the nature, timing and estimated costs of the efforts necessary to complete the development of our drug candidate projects;
|
· |
the anticipated completion dates for our drug candidate projects;
|
· |
the scope, rate of progress and cost of our clinical trials that we are currently running or may commence in the future with respect to our drug candidate projects;
|
· |
the scope, rate of progress of our preclinical studies and other R&D activities related to our drug candidate projects;
|
· |
clinical trial results for our drug candidate projects;
|
· |
the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights relating to our drug candidate projects;
|
· |
the terms and timing of any strategic alliance, licensing and other arrangements that we have or may establish in the future relating to our drug candidate projects;
|
· |
the cost and timing of regulatory approvals with respect to our drug candidate projects; and
|
· |
the cost of establishing clinical supplies for our drug candidate projects.
|
Period
|
Total Number of
Shares
Purchased (2)
|
Average
Price Paid
Per Share (3)
|
Total Number of
Shares
Purchased as
Part of Publicly
Announced Plan
|
Maximum
Number (or
Dollar Value) of
Shares that may
yet be Purchased
under the Plan
|
||||||||||||
275,014
|
$
|
3,000,000
|
(1)
|
|||||||||||||
July 1, 2018 – July 31, 2018
|
-
|
$
|
-
|
-
|
-
|
|||||||||||
August 1, 2018 – August 31, 2018
|
-
|
-
|
-
|
-
|
||||||||||||
September 1, 2018 – September 30, 2018
|
43,705
|
58.55
|
318,719
|
$ |
440,950
|
(1) |
On August 9, 2018, we announced that our Board of Directors had authorized the
repurchase of up to $3.0 million of our common stock under the stock repurchase program.
|
(2) |
The purchases were made in open-market transactions in compliance with rule 10b-18 or under the company’s 10b-18 plan.
|
(3) |
Includes commissions paid, if any, related to the stock repurchase transactions.
|
Amended Agreement of Lease, dated as of August 14, 2018, among the Company, ABC-NY and 35 Wilbur Street Associates.
|
||
31**
|
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule13a-14(a)/15d-14(a).
|
|
32**
|
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of
|
|
101*
|
The following materials from BioSpecifics Technologies Corp.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, (i) the
Condensed Consolidated Statements of Operations, (ii) the Condensed Consolidated Statements of Cash Flows, and (iii) the Notes to the Condensed Consolidated Financial Statements.
|
BIOSPECIFICS TECHNOLOGIES CORP.
|
|
(Registrant)
|
|
Date: November 9, 2018
|
/s/ Thomas L. Wegman
|
Thomas L. Wegman
|
|
President, Principal Executive Officer and
Principal Financial Officer
|